VOQUZ Labs AG Receives "BUY" Rating with Promising Yearly Outlook from NuWays AG

VOQUZ Labs AG has been evaluated by NuWays AG in their latest research update, receiving a "BUY" recommendation with a target price adjustment from €20 to €22. The analysis underscores a robust second half (H2) performance in the fiscal year 2023, showcasing significant growth in sales and profitability. Sales in H2 grew by 16% year-over-year to €3.4 million, primarily driven by its flagship product samQ, coupled with a high demand for the newly launched visoryQ, an automation tool for SAP ERP decision processes.

The full-year sales amounted to €5.2 million, marking an 11% increase from the previous year. EBITDA for H2 was reported at €0.9 million, leading to a positive annual EBITDA of €0.4 million, a turn around from previous estimates. Furthermore, the report highlights a promising FY 2024 outlook with sales growth predictions between 10-20% and an EBITDA margin target of 15-20%. These projections are supported by the anticipated benefits from the S/4HANA transition and potential up-selling opportunities.

The analysis concludes by reiterating the "BUY" rating based on VOQUZ Labs AG's solid performance, favorable market position, and the scalability of its business model. This optimistic outlook is further enriched by the stock's attractive valuation metrics.